Press release content from Business Wire. The AP news staff was not involved in its creation.
Crescent Acquisition Corp Announces Stockholder Approval of Extension of Deadline to Complete Business Combination
February 18, 2021 GMT
LOS ANGELES (BUSINESS WIRE) Feb 18, 2021
Crescent Acquisition Corp (“Crescent”) (NASDAQ: CRSA) announced today that on February 17, 2021 its stockholders approved an extension of the date by which it has to complete an initial business combination from March 12, 2021 to June 30, 2021. Crescent requested the extension in order to complete the previously announced proposed business combination (the “LiveVox Transaction”) with LiveVox Holdings, Inc. (“LiveVox”), a leading next-generation contact center platform that powers more than 14 billion interactions a year.
CrowdStrike To Acquire Log Management Startup Humio For $400M
By leveraging Humio, CrowdStrike will help developers, security analysts and IT professionals gain complete observability to explore threats and vulnerabilities and obtain insight from computer-generated data in real time, says CrowdStrike CTO Michael Sentonas. By Michael Novinson February 18, 2021, 09:23 AM EST
CrowdStrike has agreed to purchase Humio to strengthen its ability to ingest and correlate data from any log, application or feed for actionable insight and real-time protection.
The Sunnyvale, Calif.-based endpoint security giant said London-based Humio’s native ability to ingest and analyze both unstructured and semi-structured data will enhance how the CrowdStrike platform addresses DevOps and DevSecOps issues. The deal will enable CrowdStrike to provide deep, contextual index-free eXtended Detection and Response (XDR) with speed and scale.
Quotient acquisition of Arcinova aimed at ‘streamlining’ early development process for biotech and pharma companies Quotient Sciences, a drug development and manufacturing accelerator with facilities in the UK and the US, has acquired Arcinova, a UK-based multiservice contract development and manufacturing organization (CDMO).
Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide. It has been in business for over 40 years.
The combined business will continue to focus on both biotech firms and pharmaceutical companies developing small molecules for oral delivery.
As part of the deal, Arcinova’s minority equity partner, BGF, will exit the business, having backed its growth since 2018.